Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America
Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodation...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , |
| Format: | article |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/20.500.12008/53300 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1868890225292345344 |
|---|---|
| author | Martínez-Cordero, Humberto |
| author2 | Peña, Camila Schutz, Natalia Paola Bove, Virginia Villano, Fiorella Beltrán, Cecilia Donoso, Javiera López-Vidal, Hernán Roa Salinas, Macarena Alejandra Soto, Pablo Ochoa, Paola Duarte, Patricio Riva, Eloísa |
| author2_role | author author author author author author author author author author author author |
| author_browse | Beltrán, Cecilia Bove, Virginia Donoso, Javiera Duarte, Patricio López-Vidal, Hernán Martínez-Cordero, Humberto Ochoa, Paola Peña, Camila Riva, Eloísa Roa Salinas, Macarena Alejandra Schutz, Natalia Paola Soto, Pablo Villano, Fiorella |
| author_facet | Martínez-Cordero, Humberto Peña, Camila Schutz, Natalia Paola Bove, Virginia Villano, Fiorella Beltrán, Cecilia Donoso, Javiera López-Vidal, Hernán Roa Salinas, Macarena Alejandra Soto, Pablo Ochoa, Paola Duarte, Patricio Riva, Eloísa |
| author_role | author |
| collection | COLIBRI |
| dc.contributor.none.fl_str_mv | Martínez-Cordero Humberto, Instituto Nacional de Cancerología de Colombia (Colombia) Peña Camila, Hospital Del Salvador (Chile). Departamento de Hematología Schutz Natalia Paola, Hospital Italiano de Buenos Aires (Argentina) Bove Virginia, Asociación Española de Socorros Mutuos (Uruguay) Villano Fiorella, CASMU (Uruguay) Beltrán Cecilia, Hospital de Temuco (Chile) Donoso Javiera, Hospital Sótero del Río (Chile) López-Vidal Hernán, Hospital Barros Luco (Chile) Roa Salinas Macarena Alejandra, Hospital Del Salvador (Chile). Departamento de Hematología Soto Pablo, Hospital Dr. Eduardo Schütz Schroeder (Chile) Ochoa Paola, Instituto Alexander Fleming (Argentina) Duarte Patricio, CEMIC Hospital Universitario (Argentina) Riva Eloísa, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas |
| dc.coverage.none.fl_str_mv | AMÉRICA LATINA |
| dc.creator.none.fl_str_mv | Martínez-Cordero, Humberto Peña, Camila Schutz, Natalia Paola Bove, Virginia Villano, Fiorella Beltrán, Cecilia Donoso, Javiera López-Vidal, Hernán Roa Salinas, Macarena Alejandra Soto, Pablo Ochoa, Paola Duarte, Patricio Riva, Eloísa |
| dc.date.none.fl_str_mv | 2023 2026-01-29T19:19:44Z 2026-01-29T19:19:44Z |
| dc.format.none.fl_str_mv | 7 p. application/pdf |
| dc.identifier.none.fl_str_mv | Martínez-Cordero H, Peña C, Schutz N y otros. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America. JCO Global Oncology [en línea]. 2023;9. 7 p. https://hdl.handle.net/20.500.12008/53300 10.1200/GO.23.00182 2687-8941 |
| dc.language.none.fl_str_mv | en eng |
| dc.publisher.none.fl_str_mv | American Society of Clinical Oncology |
| dc.relation.none.fl_str_mv | JCO Global Oncology. 2023;9 |
| dc.rights.none.fl_str_mv | info:eu-repo/semantics/openAccess Licencia Creative Commons Atribución (CC - By 4.0) |
| dc.source.none.fl_str_mv | reponame:COLIBRI instname:Universidad de la República instacron:Universidad de la República |
| dc.subject.none.fl_str_mv | PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
| dc.title.none.fl_str_mv | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| dc.type.none.fl_str_mv | Artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| description | Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodations, Expenses: Varifarma Cecilia Beltran Consulting or Advisory Role: Takeda Travel, Accommodations, Expenses: Janssen, Takeda Javiera Donoso Honoraria: Janssen Oncology Consulting or Advisory Role: Janssen Oncology Hern´ an L´ opez-Vidal Consulting or Advisory Role: Janssen Oncology, Pfizer, AbbVie Speakers’ Bureau: Janssen Oncology Travel, Accommodations, Expenses: Janssen Oncology, Pfizer Macarena Alejandra Roa Salinas Honoraria: AbbVie, AstraZeneca, Tecnofarma Consulting or Advisory Role: Janssen, Takeda, Tecnofarma Travel, Accommodations, Expenses: Roche Pablo Soto Travel, Accommodations, Expenses: Janssen Paola Ochoa Honoraria: Janssen, Sanofi Consulting or Advisory Role: Sanofi, Janssen Travel, Accommodations, Expenses: Janssen Patricio Duarte Consulting or Advisory Role: Janssen, Sanofi, Takeda Speakers’ Bureau: Sanofi Travel, Accommodations, Expenses: Sanofi Guillermina Remaggi Consulting or Advisory Role: Janssen-Cilag, Sanofi,Pfizer Speakers’ Bureau: Janssen Travel, Accommodations, Expenses: Janssen, Sanofi Claudia Shanley Honoraria: Takeda Consulting or Advisory Role: Sanofi, AbbVie, Janssen Travel, Accommodations, Expenses: Janssen Sergio Lopresti Honoraria: Janssen Oncology Dorotea Fantl Speakers’ Bureau: Janssen, Takeda, Sanofi, Amgen Research Funding: Janssen, Takeda, Helsinn Therapeutics, Sanofi, Roche Travel, Accommodations, Expenses: Janssen, Sanofi Guillermo Quintero Consulting or Advisory Role: Janssen Oncology, Pfizer, Takeda, Sanofi Travel, Accommodations, Expenses: AbbVie, Amgen, Janssen Oncology, Roche David Gomez-Almaguer Consulting or Advisory Role: Janssen, Takeda, Teva, BMS. Speakers’Bureau:Bristol MyersSquibb(Mexico),AbbVie,Novartis,Janssen, Amgen, Takeda Luis Antonio Salazar Honoraria: Janssen, AbbVie, AstraZeneca Consulting or Advisory Role: AstraZeneca, Janssen Travel, Accommodations, Expenses: Janssen Mar´ ıa Cynthia Fuentes-Lacouture Honoraria: Fresenius Kabi BioSimiliars Travel, Accommodations, Expenses: Janssen Mario Pereira Honoraria: Novartis, Amgen, Janssen, Pint Pharma Consulting or Advisory Role: Novartis Travel, Accommodations, Expenses: AbbVie. Jule Vasquez Honoraria: Janssen, Roche Consulting or Advisory Role: Janssen, AbbVie Research Funding: Roche (Inst) Travel, Accommodations, Expenses: Janssen, AbbVie Elo´ ısa Riva Honoraria: Sanofi, Janssen, AbbVie/Genentech Research Funding: Sebia (Inst) Travel, Accommodations, Expenses: Roemmers, Janssen, Sanof |
| eu_rights_str_mv | openAccess |
| format | article |
| id | anni_eceb6bc91f41361016f08bc980b1dc6f |
| identifier_str_mv | Martínez-Cordero H, Peña C, Schutz N y otros. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America. JCO Global Oncology [en línea]. 2023;9. 7 p. 10.1200/GO.23.00182 2687-8941 |
| instacron_str | Universidad de la República |
| institution | Universidad de la República |
| instname_str | Universidad de la República |
| language | eng |
| language_invalid_str_mv | en |
| network_acronym_str | anni |
| network_name_str | oai-lr-anni |
| oai_identifier_str | oai:colibri.udelar.edu.uy:20.500.12008/53300 |
| publishDate | 2023 |
| publishDateSort | 2023 |
| publisher.none.fl_str_mv | American Society of Clinical Oncology |
| reponame_str | COLIBRI |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| spelling | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin AmericaMartínez-Cordero, HumbertoPeña, CamilaSchutz, Natalia PaolaBove, VirginiaVillano, FiorellaBeltrán, CeciliaDonoso, JavieraLópez-Vidal, HernánRoa Salinas, Macarena AlejandraSoto, PabloOchoa, PaolaDuarte, PatricioRiva, EloísaPERSONA DE MEDIANA EDADPROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICABORTEZOMIBCICLOFOSFAMIDADEXAMETASONAMIELOMA MÚLTIPLEPRONÓSTICOTALIDOMIDARESULTADO DEL TRATAMIENTOUSOS TERAPÉUTICOSQUIMIOTERAPIAEPIDEMIOLOGÍAHumberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodations, Expenses: Varifarma Cecilia Beltran Consulting or Advisory Role: Takeda Travel, Accommodations, Expenses: Janssen, Takeda Javiera Donoso Honoraria: Janssen Oncology Consulting or Advisory Role: Janssen Oncology Hern´ an L´ opez-Vidal Consulting or Advisory Role: Janssen Oncology, Pfizer, AbbVie Speakers’ Bureau: Janssen Oncology Travel, Accommodations, Expenses: Janssen Oncology, Pfizer Macarena Alejandra Roa Salinas Honoraria: AbbVie, AstraZeneca, Tecnofarma Consulting or Advisory Role: Janssen, Takeda, Tecnofarma Travel, Accommodations, Expenses: Roche Pablo Soto Travel, Accommodations, Expenses: Janssen Paola Ochoa Honoraria: Janssen, Sanofi Consulting or Advisory Role: Sanofi, Janssen Travel, Accommodations, Expenses: Janssen Patricio Duarte Consulting or Advisory Role: Janssen, Sanofi, Takeda Speakers’ Bureau: Sanofi Travel, Accommodations, Expenses: Sanofi Guillermina Remaggi Consulting or Advisory Role: Janssen-Cilag, Sanofi,Pfizer Speakers’ Bureau: Janssen Travel, Accommodations, Expenses: Janssen, Sanofi Claudia Shanley Honoraria: Takeda Consulting or Advisory Role: Sanofi, AbbVie, Janssen Travel, Accommodations, Expenses: Janssen Sergio Lopresti Honoraria: Janssen Oncology Dorotea Fantl Speakers’ Bureau: Janssen, Takeda, Sanofi, Amgen Research Funding: Janssen, Takeda, Helsinn Therapeutics, Sanofi, Roche Travel, Accommodations, Expenses: Janssen, Sanofi Guillermo Quintero Consulting or Advisory Role: Janssen Oncology, Pfizer, Takeda, Sanofi Travel, Accommodations, Expenses: AbbVie, Amgen, Janssen Oncology, Roche David Gomez-Almaguer Consulting or Advisory Role: Janssen, Takeda, Teva, BMS. Speakers’Bureau:Bristol MyersSquibb(Mexico),AbbVie,Novartis,Janssen, Amgen, Takeda Luis Antonio Salazar Honoraria: Janssen, AbbVie, AstraZeneca Consulting or Advisory Role: AstraZeneca, Janssen Travel, Accommodations, Expenses: Janssen Mar´ ıa Cynthia Fuentes-Lacouture Honoraria: Fresenius Kabi BioSimiliars Travel, Accommodations, Expenses: Janssen Mario Pereira Honoraria: Novartis, Amgen, Janssen, Pint Pharma Consulting or Advisory Role: Novartis Travel, Accommodations, Expenses: AbbVie. Jule Vasquez Honoraria: Janssen, Roche Consulting or Advisory Role: Janssen, AbbVie Research Funding: Roche (Inst) Travel, Accommodations, Expenses: Janssen, AbbVie Elo´ ısa Riva Honoraria: Sanofi, Janssen, AbbVie/Genentech Research Funding: Sebia (Inst) Travel, Accommodations, Expenses: Roemmers, Janssen, SanofPURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS Weanalyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MMage40 yearsoryoungercomparedwith256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Ofthepatients age40 yearsoryounger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly.American Society of Clinical OncologyMartínez-Cordero Humberto, Instituto Nacional de Cancerología de Colombia (Colombia)Peña Camila, Hospital Del Salvador (Chile). Departamento de HematologíaSchutz Natalia Paola, Hospital Italiano de Buenos Aires (Argentina)Bove Virginia, Asociación Española de Socorros Mutuos (Uruguay)Villano Fiorella, CASMU (Uruguay)Beltrán Cecilia, Hospital de Temuco (Chile)Donoso Javiera, Hospital Sótero del Río (Chile)López-Vidal Hernán, Hospital Barros Luco (Chile)Roa Salinas Macarena Alejandra, Hospital Del Salvador (Chile). Departamento de HematologíaSoto Pablo, Hospital Dr. Eduardo Schütz Schroeder (Chile)Ochoa Paola, Instituto Alexander Fleming (Argentina)Duarte Patricio, CEMIC Hospital Universitario (Argentina)Riva Eloísa, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas2026-01-29T19:19:44Z2026-01-29T19:19:44Z2023Artículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion7 p.application/pdfMartínez-Cordero H, Peña C, Schutz N y otros. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America. JCO Global Oncology [en línea]. 2023;9. 7 p.https://hdl.handle.net/20.500.12008/5330010.1200/GO.23.001822687-8941reponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaenengJCO Global Oncology. 2023;9AMÉRICA LATINALas obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución (CC - By 4.0)oai:colibri.udelar.edu.uy:20.500.12008/533002026-04-14T10:28:25Z |
| spellingShingle | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America Martínez-Cordero, Humberto PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
| status_str | publishedVersion |
| title | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_full | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_fullStr | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_full_unstemmed | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_short | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_sort | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| topic | PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
| url | https://hdl.handle.net/20.500.12008/53300 |